Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis
- 6 November 2007
- journal article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 147 (9), 611-619
- https://doi.org/10.7326/0003-4819-147-9-200711060-00005
Abstract
The utility of antineutrophil cytoplasmic antibody (ANCA) levels to guide the management of patients with Wegener granulomatosis remains controversial. To determine whether pro-proteinase 3 (PR3)–ANCA levels are a better measure of disease activity than mature-PR3–ANCA levels, whether decreases in either level are associated with shorter time to remission, and whether increases are followed by relapse. Prospective, observational cohort study. 8 United States medical centers that participated in a treatment trial for Wegener granulomatosis. 156 patients with Wegener granulomatosis enrolled during periods of active disease. PR3-ANCA levels (by capture enzyme-linked immunosorbent assay) and disease activity (by the Birmingham Vasculitis Activity Score for Wegener granulomatosis). The ANCA levels were only weakly associated with disease activity across patients. The longitudinal association within patients was stronger, but changes in ANCA levels explained less than 10% of the variation in disease activity. Decreases in mature- and pro-PR3–ANCA levels were not statistically significantly associated with shorter time to remission, and increases in mature-PR3–ANCA levels (adjusted hazard ratio, 0.8 [95% CI, 0.4 to 1.9]; P = 0.67) and pro-PR3–ANCA levels (adjusted hazard ratio, 1.0 [CI, 0.5 to 2.1]; P = 0.99) were not associated with relapse. The proportion of patients who had relapse within 1 year of an increase in PR3-ANCA levels was 40% for mature-PR3 (CI, 18% to 56%) and 43% for pro-PR3 (CI, 22% to 58%). Samples were collected approximately every 3 months. Sensitivity and specificity of ANCA levels for detecting remission and relapse could not be calculated because each patient had different follow-up times. Pro-PR3–ANCA is no better than mature-PR3–ANCA as a measure of Wegener granulomatosis activity. Decreases in PR3-ANCA levels are not associated with shorter time to remission, and increases are not associated with relapse. These findings suggest that ANCA levels cannot be used to guide immunosuppressive therapy.Keywords
This publication has 30 references indexed in Scilit:
- Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody–associated vasculitisArthritis & Rheumatism, 2005
- Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)Arthritis & Rheumatism, 2005
- Etanercept plus Standard Therapy for Wegener's GranulomatosisThe New England Journal of Medicine, 2005
- A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic AutoantibodiesThe New England Journal of Medicine, 2003
- Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener’s granulomatosis: extended follow-up and rate of relapseAmerican Journal Of Medicine, 2003
- An interdisciplinary approach to the care of patients with Wegener's granulomatosis: Long-term outcome in 155 patientsArthritis & Rheumatism, 2000
- Antineutrophil cytoplasmic antibodies and associated diseases: A review of the clinical and laboratory featuresKidney International, 2000
- What you should know about PR3-ANCA: Conformational requirements of proteinase 3 (PR3) for enzymatic activity and recognition by PR3-ANCAArthritis Research & Therapy, 2000
- Wegener Granulomatosis: An Analysis of 158 PatientsAnnals of Internal Medicine, 1992
- AUTOANTIBODIES AGAINST NEUTROPHILS AND MONOCYTES: TOOL FOR DIAGNOSIS AND MARKER OF DISEASE ACTIVITY IN WEGENER'S GRANULOMATOSISThe Lancet, 1985